FDA Issues Guide on Long-Acting Local Anesthetics

FDA has released a draft guidance outlining recommendations for drugmakers developing local anesthetic products designed to provide prolonged postoperative pain relief, as the agency seeks to support alternatives to opioid-based pain management. The draft guidance, titled “Development of Local Anesthetic Drug Products With Prolonged Duration of Effect,” focuses on products intended to deliver analgesia for days rather than hours following surgery. The document applies to sponsors pursuing NDAs through the 505(b) regulatory pathway and does not apply to generic drug applications or biologics.

FDA says growing interest in reducing opioid use after surgery is driving the development of modified-release local anesthetic formulations, including extended-release injectable suspensions and drug-device combination products that can slowly release anesthetics into surrounding tissue.

The agency notes that traditional local anesthetics typically provide pain relief for only a few hours, despite being widely used in procedures such as inguinal hernia repair and total knee arthroplasty.

Under the draft guidance, FDA recommends that sponsors engage with the agency early in development to discuss comparative bioavailability studies, pharmacokinetic evaluations, and clinical trial design. The guidance emphasizes a sequential development process beginning with in vitro characterization of drug release profiles, followed by pharmacokinetic studies and then safety and efficacy trials when needed.

FDA says developers should generate pharmacokinetic data for each proposed anatomical site and route of administration included in labeling, warning that systemic drug exposure may not correlate with local efficacy or safety. The agency also stresses that comparable systemic exposure between products does not necessarily demonstrate equivalent local anesthetic activity.

The guidance highlights the complexity of evaluating prolonged-duration local anesthetics because factors such as administration site, tissue vascularity, formulation characteristics, and delivery devices can significantly alter drug absorption and release patterns.

Additionally, FDA addresses combination products, including implants containing embedded anesthetics, prefilled syringes, and software-controlled delivery systems. The agency says sponsors developing such products should incorporate human factors engineering throughout development to minimize medication errors and ensure safe use.

For clinical trials, FDA recommends randomized, blinded, controlled studies that reflect current perioperative pain-management practices, including multimodal analgesic regimens. The agency says studies should evaluate both systemic and local toxicity, as well as clinically meaningful measures of pain relief and patient function.

The draft guidance distinguishes between indications for local anesthesia and local analgesia, noting that products seeking an anesthesia indication must demonstrate effects on sensory and motor function in addition to pain reduction.

FDA also encourages sponsors to evaluate multiple doses, concentrations, and dosing regimens before phase 3 trials and recommended that active comparators include currently approved immediate-release or modified-release anesthetic products representing the standard of care.